drugset / Trial / NCT00327522
Safety and Immune Response Study of an Investigational Pneumococcal Vaccine.
Non-randomizedSingle-groupOpen-labelPrevention
Summary
The purpose of this study is to evaluate the safety and immunogenicity of two doses of GSK Biologicals' 11 PCV vaccine when given to healthy subjects aged 18 to 40 years .
Timeline
- Start
- 2006-06
- Primary completion
- —
- Completion
- —
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Prevnar 13 | Vaccine | — | — |